Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia - 1 Apr 2014

Song Zhengbo, Zhang Yiping

Abstract excerpt

Survival and treatment options are limited for patients with brain metastases arising from non-small cell lung cancer (NSCLC). We evaluated erlotinib and gefitinib as salvage treatments for NSCLC patients with brain metastases that failed to respond to radiotherapy in a retrospective study. Survival was estimated using Kaplan-Meier analysis and log-rank tests. Multivariable predictors were assessed using the Cox...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Kaplan-Meier Estimate

Share to Quinazolines

Share to Salvage Therapy

Share to Treatment Failure

Source

Identifiers

PMID: 24256883
DOI: 10.1016/j.jocn.2013.05.022

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.PMID 24256883Read ↗

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.Semantic proximity Read ↗

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.Semantic proximity Read ↗

Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?Semantic proximity Read ↗

First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.Semantic proximity Read ↗

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.Semantic proximity Read ↗

Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.Semantic proximity Read ↗

Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

The diagnosis and treatment of brain metastases in EGFR mutant lung cancer.Semantic proximity Read ↗

Erlotinib for the treatment of brain metastases in non-small cell lung cancer.Semantic proximity Read ↗

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.Semantic proximity Read ↗

Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.